TREATMENT BURDEN AND PATIENT PREFERENCE IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS ON CONCIZUMAB PROPHYLAXIS: RESULTS FROM THE PHASE 3 EXPLORER7 STUDY
K Hamptona, P Knoeblb, J Odgaard-Jensenc, O Stasyshynd, JJT Zawc, JS Neergaardc, B Zulfikare, GG Fabbronf
a Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom
b Department of Medicine 1, Division of Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria
c Novo Nordisk A/S, Søborg, Denmark
d Academy of Medical Sciences of Ukraine, Lviv, Ukraine
e Department of Pediatric Hematology/Oncology, Istanbul University Oncology Institute, Istanbul, Türkiye
f Novo Nordisk Brasil, São Paulo, Brazil
Read
1277
Timeswas read the article
497
Total PDF
780
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 9 | 14 | 3 | 17 |
| 2025 8 | 54 | 25 | 79 |
| 2025 7 | 46 | 19 | 65 |
| 2025 6 | 50 | 23 | 73 |
| 2025 5 | 65 | 8 | 73 |
| 2025 4 | 32 | 12 | 44 |
| 2025 3 | 51 | 11 | 62 |
| 2025 2 | 53 | 23 | 76 |
| 2025 1 | 31 | 15 | 46 |
| 2024 12 | 24 | 16 | 40 |
| 2024 11 | 33 | 18 | 51 |
| 2024 10 | 29 | 24 | 53 |
| 2024 9 | 53 | 24 | 77 |
| 2024 8 | 39 | 25 | 64 |
| 2024 7 | 32 | 25 | 57 |
| 2024 6 | 38 | 68 | 106 |
| 2024 5 | 35 | 31 | 66 |
| 2024 4 | 28 | 18 | 46 |
| 2024 3 | 20 | 24 | 44 |
| 2024 2 | 15 | 15 | 30 |
| 2024 1 | 6 | 9 | 15 |
| 2023 12 | 12 | 21 | 33 |
| 2023 11 | 11 | 26 | 37 |
| 2023 10 | 9 | 14 | 23 |
Show all
